Shots:
- Memo has entered into a strategic collaboration & exclusive option-to-license agreement with CSL for Memo’s recombinant polyclonal IgG technology
- As per the deal, Memo will use its Dropzylla platform for cloning human antibody repertoires & polyclonal antibody expression to develop recombinant polyclonal IgG products, while CSL will obtain an option to exclusively license those candidates from Memo
- The deal includes R&D funding & technology access, with a license fee payable upon exercise of the option, plus development & sales milestones of up to CHF 265M ($328M) for the first product, alongside single-digit royalties
Ref: Globenewswire | Image: Memo & CSL | Press Release
Related News: VarmX Inks a ~$2.2B Strategic Collaboration and Option Agreement with CSL for VMX-C001 to Advance Coagulation Treatment
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
